Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of divarasib versus investigator-chosen immunotherapy or observation after complete resection in KRAS G12C-positive stage II-III non-small cell lung cancer
CTR20262969Phase 3Active
- Sponsor
- Roche
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of divarasib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Aug 2026; status: active.
02
Drugs
divarasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262969.